MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas

This publication has 33 references indexed in Scilit:

• HER2 testing in gastric cancer: a practical approach
  Laboratory Investigation, 2012
• Genetic Activation of the MET Pathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer
  Journal of Clinical Oncology, 2011
• MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
  Journal of Clinical Oncology, 2011
• 6504 ORAL Safety and Efficacy of Epirubicin, Cisplatin, and Capecitabine (ECX) Plus Rilotumumab (R) as First-line Treatment for Unresectable Locally Advanced (LA) or Metastatic (M) Gastric or Esophagogastric Junction (EGJ) Adenocarcinoma
  European Journal of Cancer, 2011
• METExpression and Amplification in Patients with Localized Gastric Cancer
  Cancer Epidemiology, Biomarkers & Prevention, 2011
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
  The Lancet, 2010
• Expression of E‐ and N‐cadherin and clinicopathology in hepatocellular carcinoma
  Pathology International, 2008
• Assessment of a HER2 scoring system for gastric cancer: results from a validation study
  Histopathology, 2008
• Increasing levels of MYC and MET co-amplification during tumor progression of a case of gastric cancer
  Cancer Genetics and Cytogenetics, 1995
• Frequent amplification of the c-met gene in scirrhous type stomach cancer
  Biochemical and Biophysical Research Communications, 1992